Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8161 - 8168 of 12089 results
Legislation to Reduce Consumer Cost-Sharing Takes a Back Burner in the Drug Pricing Debate
June 9, 2016| Blog| Viewpoint
Employers, Join Us for a Webinar: The New White-Collar Overtime Rule
June 9, 2016| Blog| Viewpoint
As Affordable Care Act Enforcement Looms, Some Lessons Learned From Massachusetts
June 8, 2016| Blog| Viewpoint
Tackling the Dragon of Hospital Price Disparity: Massachusetts's On-Going Efforts to Address Price Equity
June 8, 2016| Alert| Viewpoint
Senate Appropriations Bill Targets FDA Rulemaking Agenda
June 8, 2016| Blog| Viewpoint
ML Strategies Health Care Congressional Outlook
June 8, 2016| Blog| Viewpoint
Delays in 340B Mega-Guidance and a Recap of the Latest 340B Updates
June 7, 2016| Blog| Viewpoint
Mintz/ML Strategies Pharmacy Summit White Paper Highlights Drug Development Process
June 7, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|